ArticleDiscover oncology2025
A novel cuproptosis-related prognostic gene signature and validation of differential expression in colon cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundColon cancer is one of the most common gastrointestinal tract tumors and is increasing in incidence worldwide each year. Cuproptosis is a novel cell death pathway that is closely related to energy metabolism. Recent studies suggest that cuproptosis-related genes may play important roles in the progression of colon cancer. Therefore, we aimed to construct prognostic models and column plots for overall survival and progression-free survival of colon cancer by cuproptosis-related genes and search their relationship with immune checkpoints and immune infiltration.
methodsIn this study, we systematically analyzed the expression differences, biological functions, and variants of cuproptosis-related genes in colon cancer tissues using the The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. We analyzed the prognostic characteristics of cuproptosis-related genes in colon cancer using a multifactorial Cox proportional risk regression model and constructed a clinical prognostic model. Subsequently, we analyzed the correlations among cuproptosis-related genes, immune infiltration, and tumor stage.
resultsOur results revealed that LIPT1, PDHA1, GLS, CDKN2A, FDX1, DLD, and MTF1 were significantly differentially expressed between colon cancer and normal tissues. There was a broad correlation among cuproptosis-related genes, and their mutations were widely present in colon cancer samples. Analysis of cuproptosis-related genes revealed that their roles were primarily related to the tricarboxylic acid cycle and energy metabolism, whereas DLD, PDHB, DLAT, and PDHA1 were the core genes. Using a Cox proportional risk regression model, we revealed the DLAT, LIAS, and CDKN2A genes were associated with the prognosis of colon cancer. We developed a prognostic model based on the overall and progression-free survival of colon cancer, and the area under the curve (AUC) values for the prognostic score for predicting the 5-year overall and progression-free survival were 0.667 and 0.650, respectively. In regard to the survival analysis in terms of overall survival, a higher the risk score based on the cuproptosis-related gene profile resulted in a lower overall survival (HR = 1.67 [1.13–2.48]; log -rank p = 0.011). Progression-free survival was significantly shorter in high-risk patients (HR = 1.36 [0.96–1.93]; log-rank p = 0.084). To improve the clinical utility of the prediction model, we constructed columnar plots of overall survival and progression-free survival with a C-index of 0.810 for overall survival and 0.773 for progression-free survival. Immune infiltration analysis of colon cancer revealed that the expression levels of LIAS, DLAT, and CDKN2A were closely associated with multiple immune cells. Notably, DLAT expression in colon cancer was positively correlated with the expression levels of the immune checkpoint proteins CD274, HAVCR2, and CTLA4, whereas CDKN2A expression was positively correlated with the expression levels of PDCD1, HAVCR2, and CTLA4. We also observed that CDKN2A expression may be associated with colon cancer progression.
conclusionCuproptosis-related genes such as DLAT, LIAS, and CDKN2A possess predictive value in the context of the prognosis and progression of colon cancer, and their relationship with immune checkpoints and immune infiltration may provide a basis for further drug development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.